PMID- 35227758
OWN - NLM
STAT- MEDLINE
DCOM- 20220502
LR  - 20221221
IS  - 1872-9096 (Electronic)
IS  - 0166-3542 (Print)
IS  - 0166-3542 (Linking)
VI  - 199
DP  - 2022 Mar
TI  - Antiviral effects of deoxynojirimycin (DNJ)-based iminosugars in dengue 
      virus-infected primary dendritic cells.
PG  - 105269
LID - S0166-3542(22)00037-7 [pii]
LID - 10.1016/j.antiviral.2022.105269 [doi]
LID - 105269
AB  - Dendritic cells (DCs) are important targets for dengue virus (DENV) infection and 
      play a significant role in the early immune response. Antiviral effects of 
      iminosugars against DENV in primary cells have been demonstrated previously in 
      monocyte-derived macrophages (MDMPhis). Given the important role played by DCs in 
      innate immune defense against DENV, the antiviral effects of three 
      deoxynojirimycin (DNJ) derivatives (NN-DNJ, EOO-DNJ and 2THO-DNJ) and a 
      deoxygalactonojirimycin (DGJ) negative control were evaluated in DENV-infected 
      primary human monocyte-derived immature DCs (imDCs). DNJ- but not DGJ-derivatives 
      elicited antiviral activity in DENV-infected imDCs, similar to that observed in 
      MDMPhis. The DNJ-derivatives inhibited DENV secretion in a dose-dependent manner. 
      Endoplasmic reticulum (ER) alpha-glucosidase I inhibition by DNJ-derived iminosugars, 
      at concentrations of 3.16 muM, correlated with a reduction in the specific 
      infectivity of virions that were still secreted, as well as a reduction in 
      DENV-induced tumour necrosis factor alpha secretion. This suggests 
      iminosugar-mediated ER alpha-glucosidase I inhibition may give rise to further 
      benefits during DENV infection, beyond the reduction in viral secretion 
      associated with ER alpha-glucosidase II inhibition.
CI  - Copyright (c) 2022. Published by Elsevier B.V.
FAU - Perera, Nilanka
AU  - Perera N
AD  - Department of Biochemistry, University of Oxford, Oxford, OX1 3QU, UK; Department 
      of Medicine, Faculty of Medical Sciences, University of Sri Jayewardenepura, 
      Nugegoda, Sri Lanka. Electronic address: nilanka@sjp.ac.lk.
FAU - Brun, Juliane
AU  - Brun J
AD  - Department of Biochemistry, University of Oxford, Oxford, OX1 3QU, UK. Electronic 
      address: juliane.brun@path.ox.ac.uk.
FAU - Alonzi, Dominic S
AU  - Alonzi DS
AD  - Department of Biochemistry, University of Oxford, Oxford, OX1 3QU, UK. Electronic 
      address: dominic.alonzi@ctl.ox.ac.uk.
FAU - Tyrrell, Beatrice E
AU  - Tyrrell BE
AD  - Department of Biochemistry, University of Oxford, Oxford, OX1 3QU, UK. Electronic 
      address: beatrice.tyrrell@gmail.com.
FAU - Miller, Joanna L
AU  - Miller JL
AD  - Department of Biochemistry, University of Oxford, Oxford, OX1 3QU, UK. Electronic 
      address: joanna.miller@medsci.ox.ac.uk.
FAU - Zitzmann, Nicole
AU  - Zitzmann N
AD  - Department of Biochemistry, University of Oxford, Oxford, OX1 3QU, UK. Electronic 
      address: Nicole.zitzmann@bioch.ox.ac.uk.
LA  - eng
GR  - 203853/Z/16/Z/WT_/Wellcome Trust/United Kingdom
GR  - 105402/Z/14/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220225
PL  - Netherlands
TA  - Antiviral Res
JT  - Antiviral research
JID - 8109699
RN  - 0 (Antiviral Agents)
RN  - 19130-96-2 (1-Deoxynojirimycin)
SB  - IM
MH  - 1-Deoxynojirimycin/pharmacology
MH  - Antiviral Agents/pharmacology/therapeutic use
MH  - Dendritic Cells
MH  - *Dengue/drug therapy
MH  - *Dengue Virus
MH  - Endoplasmic Reticulum
MH  - Humans
MH  - Macrophages
PMC - PMC9760573
OTO - NOTNLM
OT  - Antiviral effects
OT  - Dendritic cells
OT  - Dengue
OT  - Iminosugars
OT  - alpha-glucosidases
COIS- Authors NP, JB, DA, BET, JLM and NZ declare that they have no known competing 
      financial interests or personal relationships that could have appeared to 
      influence the work reported in this paper.
EDAT- 2022/03/02 06:00
MHDA- 2022/05/03 06:00
PMCR- 2022/03/01
CRDT- 2022/03/01 05:47
PHST- 2021/12/05 00:00 [received]
PHST- 2022/02/12 00:00 [revised]
PHST- 2022/02/22 00:00 [accepted]
PHST- 2022/03/02 06:00 [pubmed]
PHST- 2022/05/03 06:00 [medline]
PHST- 2022/03/01 05:47 [entrez]
PHST- 2022/03/01 00:00 [pmc-release]
AID - S0166-3542(22)00037-7 [pii]
AID - 105269 [pii]
AID - 10.1016/j.antiviral.2022.105269 [doi]
PST - ppublish
SO  - Antiviral Res. 2022 Mar;199:105269. doi: 10.1016/j.antiviral.2022.105269. Epub 
      2022 Feb 25.